Signaling Pathways
-
A8557 TAE226 (NVP-TAE226)1 CitationTarget: FAKSummary: FAK inhibitor,potent and ATP-competitive
-
A8604 GNF 5Target: Bcr-AblSummary: Bcr-Abl inhibitor
-
A8620 AZD-34633 CitationTarget: ALK|Insulin-like growth factors (IGFs)Summary: ALK/IGF1R inhibitor
-
A8683 NVP-BHG712Target: Eph Receptors|VEGFRSummary: EphB4 inhibitor,potent and selective
-
B1402 GZD824Target: Bcr-AblSummary: Bcr-Abl inhibitor,novel orally bioavailable
-
B2173 CP-673451Target: PDGFRSummary: PDGFRα/β inhibitor,potent and selective
-
B1404 DCC-2036 (Rebastinib)Target: FLT3|Bcr-Abl|Tie-2|KDRSummary: Bcr-Abl inhibitor
-
B2284 Fostamatinib (R788)Target: SykSummary: Spleen tyrosine kinase (Syk) inhibitor
-
B1439 Golvatinib (E7050)Target: VEGFRSummary: C-Met/VEGFR-2 inhibitor
-
B1262 HG-10-102-011 CitationTarget: LRRK2Summary: LRRK2 inhibitor